4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 113 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 2.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $98,000 | +71.9% | 4,687 | +159.0% | 0.00% | – |
| Q1 2024 | $57,000 | -78.7% | 1,810 | -86.3% | 0.00% | – |
| Q4 2023 | $268,000 | +222.9% | 13,237 | +104.1% | 0.00% | – |
| Q3 2023 | $83,000 | +40.7% | 6,485 | +101.2% | 0.00% | – |
| Q2 2023 | $59,000 | +96.7% | 3,223 | +84.8% | 0.00% | – |
| Q1 2023 | $30,000 | -61.5% | 1,744 | -49.8% | 0.00% | – |
| Q4 2022 | $78,000 | +2500.0% | 3,471 | +697.9% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 435 | +108.1% | 0.00% | – |
| Q2 2022 | $1,000 | -96.3% | 209 | -88.1% | 0.00% | – |
| Q1 2022 | $27,000 | -77.1% | 1,756 | -67.4% | 0.00% | – |
| Q4 2021 | $118,000 | +87.3% | 5,382 | +129.6% | 0.00% | – |
| Q3 2021 | $63,000 | +293.8% | 2,344 | +247.3% | 0.00% | – |
| Q2 2021 | $16,000 | -48.4% | 675 | -5.3% | 0.00% | – |
| Q1 2021 | $31,000 | – | 713 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |